FDA On Trial Registries: Manufacturers Should Steer Clear Of Claims
Executive Summary
Manufacturers should be cautious about drawing explicit conclusions about the outcome of clinical trials posted on public registries, FDA Division of Drug Marketing, Advertising & Communications Director Tom Abrams told a Pharma Audioconference Oct. 26